The content you need, when you need it.
(8)
Endocrine Today on Healio.com brings readers breaking and industry news related to endocrine health, featuring updates from journals, meetings, industry announcements, FDA updates and clinical perspectives. Designed as an in-depth specialty clinical information website, Healio.com brings medical professionals the best news reporting, dynamic multimedia, question-and-answer columns, CME and other e
ducational activities in a variety of formats, quick reference content, blogs, peer-reviewed journals and a full line of popular book titles.
👨👩👧The odds for developing type 1 diabetes may be greater if you have a father with type 1 diabetes rather than a mother.
Read more ⬇️
Both children and adults are more likely to be diagnosed with type 1 diabetes if they have a father with type 1 diabetes vs. a mother with the condition, according to a speaker. In an analysis of 11,475 people with type 1 diabetes from five study cohorts presented at the European Association for the...
🚨 Monlunabant, a novel small molecule oral cannabinoid receptor 1 inverse agonist, induced more weight loss than placebo in a phase 2a trial enrolling adults with obesity and metabolic syndrome.
Read more about these topline results 👇
Novo Nordisk announced that monlunabant, a novel small molecule oral cannabinoid receptor 1 inverse agonist, was associated with weight loss in a phase 2a study of people with obesity and metabolic syndrome. According to a press release from the company announcing top-line results, the study include...
📰Adding semaglutide to automated insulin delivery can improve time in range, HbA1c and body weight for adults with type 1 diabetes.
Learn more 👇
In a small study of patients with type 1 diabetes using an automated insulin delivery system, semaglutide improved glucose control vs. placebo, researchers reported at the European Association for the Study of Diabetes Annual Meeting. “Despite the recent advances in diabetes care, including th...
💉Adults with type 1 diabetes achieved significant reductions in HbA1c and body weight while using semaglutide or tirzepatide off-label, according to data presented at EASD 2024.
Read more 👇
Adults with type 1 diabetes using either semaglutide or tirzepatide off-label had greater decreases in body weight and HbA1c than those not treated with either medication, according to a speaker. As Healio previously reported, researchers at the Barbara Davis Center for Diabetes at University of Col...
🦠Metformin may lower the risk for developing long COVID, according to an electronic health record review of adults with type 2 diabetes who tested positive for COVID-19.
Read more 👇
Adults with type 2 diabetes using metformin before or during a SARS-CoV-2 infection may have a lower risk for long COVID than those using other diabetes medications, according to findings published in Diabetes Care. “In this retrospective cohort study in adults with type 2 diabetes and prevale...
📰The dual SGLT1/SGLT2 inhibitor sotagliflozin improved time in range and other CGM metrics for adults with type 2 diabetes using basal insulin.
Learn more ⤵️
In patients with basal insulin-treated type 2 diabetes, sotagliflozin was associated with greater time in range compared with placebo at 18 weeks, researchers reported at the European Association for the Study of Diabetes Annual Meeting. “Sotagliflozin is a dual SGLT1 and SGLT2 inhibitor that...
🚨 Oral infigratinib has received FDA breakthrough therapy designation after increased annualized height velocity for children with achondroplasia in a phase 2 study.
Read more 👇
An oral medication to treat children with achondroplasia has received breakthrough therapy designation from the FDA, BridgeBio Pharma announced. The FDA has granted breakthrough therapy designation to infigratinib (BridgeBio Pharma) as a therapeutic option to treat achondroplasia. The designation wa...
💊An novel oral amylin and GLP-1 receptor coagonist induced up to 13.1% weight loss at 12 weeks and had no significant safety issues for adults with obesity in a phase 1 trial.
Read more ⬇️
In a first-in-human study, a novel oral amylin and GLP-1 receptor coagonist was safe and tolerable and lowered weight compared with placebo at 12 weeks in patients with obesity, researchers reported. Agnes Gasiorek, PhD, MSc Pharm, senior clinical pharmacology specialist at Novo Nordisk, presented t...
Here’s your chance to win an Apple Watch® Series 9! Take our brief survey to refine and elevate your Healio experience. Enter to win here: https://bit.ly/3TrnM9Y
🚨The Eversense 365, a CGM system with an implantable sensor lasting up to 1 year, has received FDA clearance for type 1 and type 2 diabetes.
Read more about this news ⬇️
The FDA has cleared a continuous glucose monitoring system with an implantable sensor that can be worn for up to 1 year for adults aged 18 years and older with type 1 or type 2 diabetes, according to a press release. The Eversense 365 (Senseonics and Ascensia Diabetes Care) is a CGM system that incl...
☕Drinking 201 mg to 300 mg caffeine or approximately three cups of coffee daily may lower one’s risk for developing multiple cardiometabolic diseases such as type 2 diabetes, CHD or stroke.
Learn more 👇
Adults who drink caffeinated beverages such as coffee or tea may have a lower risk for developing multiple cardiometabolic diseases compared with adults with low or no intake, according to study findings. In an analysis of data from the UK Biobank published in The Journal of Clinical Endocrinology &...
🩺In a subanalysis of the SELECT trial, semaglutide lowers the risk for MACE, regardless of kidney function, among adults with obesity.
Learn more ⬇️
In patients with obesity and heart disease, semaglutide 2.4 mg reduced risk for major adverse cardiovascular events regardless of baseline kidney function, according to new data from the SELECT trial. As Healio previously reported, in the main results of SELECT, semaglutide 2.4 mg (Wegovy, Novo Nord...
📰The GLP-1/glucagon dual agonist mazdutide outperformed dulaglutide for HbA1c decreased and weight loss among adults with type 2 diabetes.
Read more about the phase 3 DREAMS-2 trial 👇
A once-weekly GLP-1/glucagon dual agonist conferred greater decreases in HbA1c and body weight than the GLP-1 receptor agonist dulaglutide for adults with type 2 diabetes, according to a presenter. As Healio previously reported, mazdutide (Eli Lilly/Innovent) is one of several GLP-1/glucagon dual ag...
💉Dapiglutide 4 mg and 6 mg were not tied to greater weight loss than placebo for adults with obesity in a phase 2a trial. However, the company has seen positive results in a trial using 13 mg of the drug.
Read more ⤵️
A dual GLP-1/GLP-2 receptor agonist did not confer greater body weight reductions for adults with obesity and without diabetes at 12 weeks compared with placebo, according to data from a phase 2a proof-of-concept study. Dapiglutide (Zealand Pharma) is a once-weekly subcutaneous dual GLP-1/GLP-2 rece...
Continuing medical education is a journey—one filled with milestones, discoveries, and achievements.
Whether you're just starting out or looking to advance further, we’re here to help you navigate your path, track your progress, and achieve your goals.
📍Map out your journey with our one-of-a-kind dashboard now: https://shorturl.at/lk284
💊 Tirzepatide confers a similar risk for GI adverse events and lower risk for diabetic retinopathy and pancreatitis than GLP-1 receptor agonists.
Read more 👇
Tirzepatide is associated with similar odds for gastrointestinal adverse events and a lower likelihood for diabetic retinopathy and pancreatitis compared with GLP-1 receptor agonists, according to a presenter. “Our analysis of the FDA Adverse Events Reporting System database suggests that, des...
🩺Adults with diabetes with HF have a similar risk reduction for CV death or worsening HF with finerenone as people without diabetes.
Read more ⤵️
In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone improved outcomes compared with placebo regardless of baseline diabetes status, according to new data from the FINEARTS-HF trial. In addition, in patients without diabetes at baseline, those assigned fineren...
📰Adults with type 2 diabetes who lose more weight at 1 year with tirzepatide may be more likely to maintain glycemic control long term.
Read more 👇
Adults with type 2 diabetes at high risk for cardiovascular events were more likely to sustain an HbA1c of 6.5% or less at 2 years with tirzepatide if they lost more weight and had improved beta-cell function, according to new data. As Healio previously reported, tirzepatide (Mounjaro/Zepbound, Eli....
🍗The risk for incident type 2 diabetes increases for adults who eat more meat in their diet.
Read more ⬇️
Adults who eat greater amounts of meat may have increased risk for developing type 2 diabetes, according to data published in The Lancet Diabetes & Endocrinology. In a meta-analysis of data from 1,966,444 adults without diabetes at baseline from across the world, researchers found the risk for d...
📰Once-daily liraglutide induced a larger reduction in BMI for children with obesity than placebo, with a safety profile similar to what was seen in adult and adolescent trials.
Read more about the SCALE Kids trial 👇
Children with obesity receiving once-daily liraglutide 3 mg had a greater reduction in BMI at 56 weeks than those receiving placebo, according to data presented at the European Association for the Study of Diabetes annual meeting. As Healio previously reported, the FDA previously approved once-daily...
🥦 Young children who are at high genetic risk for type 1 diabetes may see their risk for progression to the disease increase based on the foods they eat.
Read more ⬇️
Young children at high genetic risk for type 1 diabetes may be more likely to progress to the disease based on their dietary intake, according to a presenter at the European Association for the Study of Diabetes annual meeting.In a prospective longitudinal analysis, researchers found eating more rye...
🚨Once-weekly insulin efsitora reduced HbA1c similarly to insulin degludec in two QWINT trials. However, concerns were raised regarding hypoglycemia rates for adults with type 1 diabetes in the QWINT-5 trial.
Read more 👇
Once-weekly insulin efsitora alfa provided similar reductions in HbA1c as once-daily insulin degludec among insulin-naive adults with type 2 diabetes and adults with type 1 diabetes previously receiving a basal and bolus insulin analog. During a symposium at the European Association for the Study of...
📰EDCs found in cholinergic medications and personal care products may activate hormone receptors and lead to early puberty for children, according to an in vitro study.
Read more on these new findings 👇
Some types of endocrine-disrupting chemicals may act as kisspeptin or gonadotropin-releasing hormone receptor agonists and could induce early puberty for children, according to in vitro findings published in Endocrinology.Researchers screened a large library of licensed pharmaceuticals and environme...
📰Once-weekly batoclimab lowered T3 and T4 below the upper limit of normal and cut immunoglobulin levels for the majority of adults with uncontrolled Graves’ disease in a phase 2a trial.
Read more 👇
Most adults who had uncontrolled Graves’ disease on antithyroid drugs responded to once-weekly subcutaneous batoclimab, according to top-line results released by Immunovant. In a phase 2a trial, people with uncontrolled Graves’ disease who had hyperthyroidism despite antithyroid drug the...
💊An oral GLP-1 receptor agonist induced 5.5% weight loss at 28 days for adults with overweight or obesity receiving a 740 mg dose in a phase 1 trial.
Learn more about these topline results ⬇️
A novel oral GLP-1 receptor agonist was well-tolerated and linked with weight loss compared with placebo in healthy adults with overweight or obesity, according to top-line results of a phase 1 study. In, a phase 1 study of TERN-601 (Terns Pharmaceuticals), an oral GLP-1 receptor agonist, participan...
🚨 A 3-day disposable insulin patch pump with a 300 U insulin reservoir from Embecta recently received FDA clearance for both type 1 and type 2 diabetes.
Learn more 👇
The FDA has granted 510(k) clearance for an insulin patch pump for adults with type 1 or type 2 diabetes, Embecta Corp. announced. The FDA cleared Embecta’s disposable insulin delivery system, which includes a tubeless patch pump with a 300 U insulin reservoir that allows for adjustable basal...
🤰Pregnant women with diabetes may improve their glycemic control with use of an automated insulin delivery system.
Learn some tips about using automated insulin delivery during pregnancy 👇
Pregnant women with diabetes can use automated insulin delivery systems with settings optimized to achieve tight glycemic targets, according to two speakers at the Association of Diabetes Care and Education Specialists annual meeting. Kevin Malloy, PharmD, BCPS, BC-ADM, CDCES, an endocrinology clini...
📰In this Q&A, Jan Kavookjian, PhD, MBA, FAPhA, FADCES, discusses ways providers can discuss type 1 diabetes screening with families and people at risk for the disease.
Read the full Q&A ⬇️
With new guidance now available on monitoring people with early-stage type 1 diabetes, it is crucial for providers to encourage people at high risk to get tested, according to a presenter. As Healio previously reported, a consensus document published in Diabetologia in June gave providers guidance o...
🤰Exposure to higher levels of PFAS during pregnancy could lead to increased body weight and worse cardiometabolic health later in life.
Read more about this new study ⤵️
Exposure to higher amounts of some types of per- and polyfluoroalkyl substances during pregnancy may lead to long-term increases in body weight, waist circumference and fat mass, according to new findings. “Three studies, to our knowledge, have assessed the association between PFAS plasma conc...
🚨 Insulin efsitora alfa was noninferior to a pair of basal insulins in two groups of adults with type 2 diabetes.
Read more about these new topline results from the QWINT trial program ⬇️
A novel once-weekly basal insulin conferred noninferior HbA1c reductions compared with daily insulins for insulin-naive adults with type 2 diabetes and those who switched from daily injections, according to topline results from two trials. Once-weekly insulin efsitora alfa (Eli Lilly) is being asses...
West Deptford, NJ
Be the first to know and let us send you an email when Endocrine Today posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
Send a message to Endocrine Today:
Today is a day for reflection, celebration, and strength. We wish you all a festive and meaningful #Juneteenth. #FreedomDay
We wish you a safe and happy #MemorialDay 🎖️ #RememberOurVets #MilitaryHonor
Your hint of the day is here! This is one word you will probably never forget. Guess now: https://bit.ly/3L1eafv
Ready to put your medical knowledge to the test? Play WORD DOC and aim for a new streak! Then, challenge your friends and see who comes out on 💪 top: https://bit.ly/3L1eafv
“Acceptance is the key to unlocking the potential of every person.” – Temple Grandin ♾️ #AutismAcceptanceMonth2024 #ASD #Healio
Did you know #Healio's #ResidencytoRetirement collection gives you #financialplanning insights like #taxreduction strategies and #assetprotection? This week, take time to learn how you can save for your future, no matter what stage of your career you're in. 💰 Healio.com/Retirement #AmericaSavesWeek #ASW2024
We hope every-bunny has an egg-cellent Easter! 🐰🐣 #HoppyEaster #Easter2024 #Healio
Your March Madness bracket might already be busted, but there's still a chance for you to become the ultimate WORD DOC champion. 🏀 Join the frenzy and guess today's word to get started! https://bit.ly/3L1eafv
Are you feeling the luck of the I-R-I-S-H? ☘️ 🌈 Put your luck to the test with today’s WORD DOC challenge! https://bit.ly/3L1eafv
We're wishing you all the happiness and luck your life can hold, today and every day. 🌈☘️ #StPatricksDay2024 #HappyStPatricksDay #Healio
🗣️ CALLING ALL NEW #RESIDENTS Congratulations on your match! Residency to Retirement will help get your financial plans in check during your #residency and beyond ✅ Read up on #financialplanning, #investments and more: Healio.com/Retirement #MatchDay2024 #Healio
Ready to flex your medical vocab muscles? 💪 Compete with a friend and see who can guess faster. Start playing today! https://bit.ly/3L1eafv
The only thing better than WORD DOC is some friendly competition. 🎉 Send this link to your colleagues and see who can guess today’s word the fastest: https://bit.ly/3L1eafv
"History has shown us that courage can be contagious, and hope can take on a life of its own." –Michelle Obama #BlackHistoryMonth2024 #Healio
Show your brain a little love ❤️ with today’s WORD DOC! Think you can get it in 6 guesses or less? Give it a shot: https://bit.ly/3L1eafv
Roses are red 🌹 Violets are blue 💙 Happy Valentine’s Day, from us to you ❣️ #Healio #ValentinesDay2024
Elizabeth Yeu, MD, FACS specializes in both Cornea and Cataract Surgery in ophthalmology. Discover customized content, curated by voices you trust at https://bit.ly/3Yk9xDe
Leonard H. Calabrese, DO delivers a unique perspective on the latest developments, trends, and breakthroughs in the field of rheumatology, making this column a must-read for health care professionals. Learn more about Healio’s trusted voices at https://bit.ly/3Yk9xDe
2023 brought about many new WORD DOC players. However, one player defeated them all with an 😱 insane high streak of 550! 🏆 Congratulations to Jake C. 🏆 Get started on your win streak for 2024 today: https://bit.ly/3L1eafv
Leonard H. Calabrese, DO delivers a unique perspective on the latest developments, trends, and breakthroughs in the field of rheumatology, making this column a must-read for healthcare professionals. Learn more about Healio’s trusted voices at https://bit.ly/3Yk9xDe
